ADP355 activates hepatic LDLR expression and ameliorates lipid metabolism in both wild type and apoE−/− mice and inhibits atherosclerosis in apoE−/− mice at 1 mg/kg/day administered for 12 weeks (37). Here, APOE is linked to atherosclerosis.